Translational Development Acquisition Corp.NASDAQ: TDAC

Translational Development Acquisition Corp. SEC 10-Q Report

· TradingView

Translational Development Acquisition Corp., a blank check company incorporated in the Cayman Islands, has released its Form 10-Q report for the quarter ended September 30, 2025. The report provides a detailed overview of the company's financial performance and operational activities, highlighting its focus on effecting a business combination by June 24, 2026.

Financial Highlights

Net Income: The company reported a net income of $1.66 million for the three months ended September 30, 2025. This was primarily driven by dividends and interest earned on marketable securities held in the Trust Account amounting to $1.87 million, partially offset by general and administrative costs of $213,658.

For the nine months ended September 30, 2025, the net income was $4.77 million, mainly due to dividends and interest earned on marketable securities held in the Trust Account totaling $5.67 million. This was offset by general and administrative costs of $782,193 and an unrealized loss on marketable securities held in the Trust Account of $125,346.

Basic and Diluted Net Income Per Share: The basic and diluted net income per redeemable Class A ordinary share was $0.08 for the three months ended September 30, 2025, and $0.22 for the nine months ended September 30, 2025. Similarly, the basic and diluted net income (loss) per non-redeemable Class B ordinary share was $0.08 for the three months ended September 30, 2025, and $0.22 for the nine months ended September 30, 2025.

Business Highlights

Business Overview: Translational Development Acquisition Corp. is focused on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. As of September 30, 2025, the company has not commenced any operations. All activities to date have been related to the company's formation, the initial public offering, and identifying a target company for a business combination.

Operational Activities: The company operates as a single reportable segment, with the Chief Financial Officer acting as the chief operating decision maker. The focus is on net income or loss and total assets as key metrics.

Future Outlook: The company plans to complete a business combination by June 24, 2026. Management is focused on identifying and evaluating target businesses, performing due diligence, and negotiating a business combination.

Liquidity and Capital Resources: As of September 30, 2025, the company had $47,150 in cash and a working capital deficit of $342,263. The company intends to use funds held outside the trust account for operational activities related to completing a business combination.

Going Concern: There is substantial doubt about the company's ability to continue as a going concern if it does not complete a business combination by June 24, 2026. The company plans to address this by completing a business combination and receiving working capital from its sponsor.

Management's Discussion: The company expects to incur significant costs in pursuit of its acquisition plans and does not anticipate generating operating revenues until after completing its initial business combination.

SEC Filing:

Earlier from Translational Development Acquisition

All Translational Development Acquisition news releases